Dr. Ron Adelman, MD, MPH, FACS with the Yale Eye Center discusses the improved treatment for wet macular degeneration, which has moved away from laser treatments and has become safer and more effective.

References and Resources
Rosenfeld, P., et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. New Engl J Med. 2006;355(14):1419-1431.

Avery, R., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372.

Goff, M., et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina. 2007;27(4):432-438.

Brown, D., et al. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. New Engl J Med. 2006;355(14):1432-1444.

For more on Dr. Adelman, visit:
med.yale.edu

Sponsored by The Doctor’s Channel